CALCITONIN GENE-RELATED PEPTIDE (CGRP) ANTAGONISTS
Vyepti is a prescription drug approved by the U.S. Food and Drug Administration (FDA) as preventative treatment for migraine in adults. Vyepti is also referred to by its drug name, eptinezumab-jjmr.
Vyepti is a biologic drug and a type of monoclonal antibody called a calcitonin gene-related peptide (CGRP) antagonist. It works by blocking CGRP, which is a protein that can cause migraine headaches.
How do I take it?
Prescribing information states that Vyepti is administered by intravenous (IV) infusion every three months.
The FDA-approved label for Vyepti lists common side effects including scratchy throat, stuffy nose, and allergic reactions including skin changes like a rash. Most allergic or hypersensitivity reactions were not serious. Some serious allergic reactions may occur in people taking Vyepti, including swelling of the skin.
For more details about this treatment, visit:
Vyepti — Lundbeck
Eptinezumab-jjmr Injection — Medline Plus